Reusable blood hemodialyzer market seen reaching $5.67 billion by 2030

The reusable blood hemodialyzer market is projected to rise from $4.16 billion in 2025 to $4.41 billion in 2026, with growth driven by chronic kidney disease, higher healthcare spending and expanding dialysis access. The Business Research Company says North America led the market in 2025 while Asia-Pacific is set to grow fastest through 2030.

Why it matters: - Reusable blood hemodialyzers are central to dialysis care for patients with chronic kidney disease, a condition that continues to expand global demand for renal treatment. - The market is shifting toward lower-cost, sustainable devices as healthcare systems look for ways to support more dialysis patients. - The Business Research Company projects the market will reach $5.67 billion by 2030, up from $4.41 billion in 2026.

What happened: - The Business Research Company released a report on the reusable blood hemodialyzer market on Sept. 29, 2026. - The report estimates the market will grow from $4.16 billion in 2025 to $4.41 billion in 2026. - The report forecasts a compound annual growth rate of 6.2% from 2025 to 2026 and 6.4% through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Reusable blood hemodialyzers, often described as artificial kidneys, filter toxins, excess fluids and waste from the bloodstream during hemodialysis. - The devices are designed to be cleaned, disinfected, tested and reused multiple times by the same patient under clinical guidelines. - The report points to rising chronic kidney disease, more dialysis centers, affordable renal care demand, and improving healthcare infrastructure in emerging markets as key growth drivers. - Improved reimbursement policies for hemodialysis treatments have also supported market expansion. - The report says reusable dialyzer adoption is being supported by high-performance reusable products and broader access to renal replacement therapies. - Key trends include dialyzer reprocessing technology, biocompatible membrane materials, stricter infection control standards and preference for multi-use devices in chronic care settings. - Chronic kidney disease is a major driver because patients need ongoing blood filtration when kidneys can no longer perform adequately. - The Australian Institute of Health and Welfare said in May 2026 that CKD accounted for 1.1% of Australia’s total disease burden in 2024. - Rising healthcare spending is another driver because it supports dialysis infrastructure, reprocessing systems and care quality. - The UK’s Office for National Statistics reported total healthcare spending rose 5.6% from 2022 to 2023, compared with 0.9% growth in 2022. - Population aging is also expanding demand, especially as more older adults require long-term dialysis management. - The Population Reference Bureau projected in January 2024 that Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That shift would lift the senior share of the U.S. population from 17% to 23%. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also promoted new report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables. - The report offers a free sample and a full version online via the sample request page and the full report.

Between the lines: - The report frames reusable dialyzers as a cost-conscious option for chronic dialysis markets, especially where healthcare systems need to scale treatment without sharply raising costs. - The regional split suggests mature markets remain important, but the strongest growth opportunity is moving toward regions with expanding healthcare access and rising kidney disease prevalence. - The emphasis on infection control and reprocessing technology shows the market is balancing reuse economics with safety requirements.

What's next: - The market is expected to keep expanding through 2030 as CKD prevalence, aging populations and dialysis access continue to rise. - Reprocessing improvements and membrane innovation are likely to shape product competition. - Asia-Pacific’s growth trajectory will be a key indicator for where future dialysis demand is concentrating.

The bottom line: - Reusable blood hemodialyzers remain a steady-growth medical device market, with demand anchored by chronic kidney disease, aging populations and the push for more affordable dialysis care.